ROCKVILLE, Md. & EDMONTON, Alberta–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) is set to unveil Phase 1 study results for its investigational therapy AUR200. The biopharmaceutical company announced it will host a webcast and conference call on June 30, 2025, at 8:30 a.m. ET to delve into these findings. Investors and interested parties can access the webcast link [here](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fevent.choruscall.com%2Fmediaframe%2Fwebcast.html%3Fwebcastid%3DE7aNqqNL&esheet=54283397&newsitemid=20250629847355&lan=en-US&anchor=here&index=1&md5=f18b28b9ed7ac35208d531f5b7b241c1). For those preferring to join via conference call, please dial 877-407-9170 or +1 201-493-6756. International participants can find dial-in numbers [here](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fcan01.safelinks.protection.outlook.com%2F%3Furl%3Dhttp%253A%252F%252Fwww.incommconferencing.com%252Finternational-dial-in&data=05%257C02%257CRMeister%2540auriniapharma.com%257Ca3fcab3d205a43d8d2d608ddb58d45a2%257C2ae9339148124f01bdb23fc941209611%257C0%257C0%257C638866340547812738%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C&sdata=%252Byb1NBlfq8o0xFuiBKsQ30EXN7p6QX0OFZOlwy%252Bf43w%253D&reserved=0&esheet=54283397&newsitemid=20250629847355&lan=en-US&anchor=here&index=2&md5=6b1054374c7810a42bcf86711e81dbb1). The company plans to make a replay of the webcast available on its website following the event.
About Aurinia
Aurinia is a biopharmaceutical firm dedicated to developing transformative therapies for patients battling autoimmune diseases with significant unmet medical needs. Shifting the treatment landscape, Aurinia launched LUPKYNIS® (voclosporin) in January 2021, marking the first FDA-approved oral medication for adult patients with active lupus nephritis. Beyond its current offerings, Aurinia is advancing AUR200, a dual inhibitor targeting B cell-activating factor (BAFF) and proliferation-inducing ligand (APRIL), with the potential to change the paradigm for treating various autoimmune conditions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250629847355/en/
Source: Aurinia Pharmaceuticals Inc.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/3605.html
